Recently, several studies have proved the overexpression of CD276 on a variety of TME cells, as well as hematologic and solid tumors, including leukemia (131), prostate cancer (132), melanoma (133), neuroblastoma (134), osteosarcoma (135), and CNS tumors (136). The gene discussed is CD276; the disease is central nervous system neoplasm.